Tibet Rhodiola Pharmaceutical Holding Co - Asset Resilience Ratio
Tibet Rhodiola Pharmaceutical Holding Co (600211) has an Asset Resilience Ratio of 15.57% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Tibet Rhodiola Pharmaceutical Holding Co (600211) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Tibet Rhodiola Pharmaceutical Holding Co's Asset Resilience Ratio has changed over time. See Tibet Rhodiola Pharmaceutical Holding Co (600211) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Tibet Rhodiola Pharmaceutical Holding Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Tibet Rhodiola Pharmaceutical Holding Co worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥995.32 Million | 15.57% |
| Total Liquid Assets | CN¥995.32 Million | 15.57% |
Asset Resilience Insights
- Good Liquidity Position: Tibet Rhodiola Pharmaceutical Holding Co maintains a healthy 15.57% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Tibet Rhodiola Pharmaceutical Holding Co Industry Peers by Asset Resilience Ratio
Compare Tibet Rhodiola Pharmaceutical Holding Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Tibet Rhodiola Pharmaceutical Holding Co (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Tibet Rhodiola Pharmaceutical Holding Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 28.45% | CN¥1.78 Billion ≈ $260.89 Million |
CN¥6.27 Billion ≈ $917.12 Million |
+7.87pp |
| 2024-12-31 | 20.57% | CN¥976.62 Million ≈ $142.91 Million |
CN¥4.75 Billion ≈ $694.68 Million |
+9.34pp |
| 2023-12-31 | 11.23% | CN¥515.34 Million ≈ $75.41 Million |
CN¥4.59 Billion ≈ $671.27 Million |
-8.10pp |
| 2022-12-31 | 19.33% | CN¥792.49 Million ≈ $115.97 Million |
CN¥4.10 Billion ≈ $599.87 Million |
+5.19pp |
| 2021-12-31 | 14.14% | CN¥537.87 Million ≈ $78.71 Million |
CN¥3.80 Billion ≈ $556.45 Million |
+13.64pp |
| 2020-12-31 | 0.51% | CN¥14.96 Million ≈ $2.19 Million |
CN¥2.94 Billion ≈ $430.84 Million |
-2.74pp |
| 2019-12-31 | 3.25% | CN¥90.00 Million ≈ $13.17 Million |
CN¥2.77 Billion ≈ $404.93 Million |
+0.41pp |
| 2016-12-31 | 2.84% | CN¥65.00 Million ≈ $9.51 Million |
CN¥2.29 Billion ≈ $335.20 Million |
+2.80pp |
| 2010-12-31 | 0.04% | CN¥308.80K ≈ $45.19K |
CN¥735.47 Million ≈ $107.62 Million |
-0.05pp |
| 2009-12-31 | 0.10% | CN¥709.60K ≈ $103.84K |
CN¥743.70 Million ≈ $108.83 Million |
+0.08pp |
| 2008-12-31 | 0.01% | CN¥112.40K ≈ $16.45K |
CN¥829.66 Million ≈ $121.41 Million |
-0.03pp |
| 2007-12-31 | 0.04% | CN¥339.80K ≈ $49.72K |
CN¥831.96 Million ≈ $121.74 Million |
+0.01pp |
| 2006-12-31 | 0.03% | CN¥252.00K ≈ $36.88K |
CN¥866.90 Million ≈ $126.86 Million |
+0.02pp |
| 2005-12-31 | 0.01% | CN¥114.60K ≈ $16.77K |
CN¥820.62 Million ≈ $120.08 Million |
-0.46pp |
| 2004-12-31 | 0.48% | CN¥3.69 Million ≈ $540.55K |
CN¥777.25 Million ≈ $113.74 Million |
-0.03pp |
| 2003-12-31 | 0.51% | CN¥3.81 Million ≈ $557.96K |
CN¥754.36 Million ≈ $110.39 Million |
+0.05pp |
| 2002-12-31 | 0.46% | CN¥3.37 Million ≈ $492.55K |
CN¥733.08 Million ≈ $107.27 Million |
-- |
About Tibet Rhodiola Pharmaceutical Holding Co
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu ca… Read more